Review for New Drug Therapies under the Newfoundland and Labrador Prescription Drug Program

The province of Newfoundland and Labrador is participating in four initiatives related to the sharing of resources in reviewing submissions for coverage under the NLPDP, the **Atlantic Common Drug Review (ACDR)**, the **National Common Drug Review (CDR)**, the **Pan-Canadian Oncology Drug Review (pCODR)** and the **Pan-Canadian Pricing Alliance (PCPA).**

I. The **Atlantic Common Drug Review (ACDR)** assesses the clinical and cost effectiveness of drugs that do not fall under the mandates of the National Common Drug Review (CDR) or the Pan-Canadian Oncology Drug Review (pCODR), and provides formulary listing recommendations to the provincially funded drug plans in Atlantic Canada.

The submission requirements for ACDR can be found at:

http://novascotia.ca/dhw/pharmacare/atlantic-common-drug-review.asp#requirements

An electronic copy of this submission including a province–specific Budget impact assessment must also be sent to NIDPF_NLPDPdrugsubmission@gov.nl.ca

II. The **National Common Drug Review (CDR)**, at the Canadian Agency for Drugs and Technologies in Health (CADTH), is a pan-Canadian process for conducting objective, rigorous reviews of the clinical, cost –effectiveness and patient evidence for drugs. CDR also provides formulary listing recommendations to Canada's publicly funded drug plans (except Quebec).

The submission requirements for CDR can be found:

https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/common-drug-review-submissions/guidelines-procedures-templates

An electronic copy of this submission including a province-specific budget impact assessment must also be sent to NIDPF_NLPDPdrugsubmission@gov.nl.ca

III. The **Pan-Canadian Oncology Drug Review (pCODR)** was established by the provincial and territorial Ministries of Health excluding Quebec to assess the clinical evidence and cost effectiveness of new cancer drugs and use this information to make recommendations to the provinces and territories to guide their drug funding decisions.

The submission requirements for pCODR can be found at:

https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s%20Drug%20Review%20Process/pcodr-submission-guidelines.pdf

An electronic copy of this submission including a province-specific budget impact assessment must be sent to NIDPF_NLPDPdrugsubmission@gov.nl.ca.

IV. The **Pan-Canadian Pharmaceutical Alliance (PCPA)** conducts joint provincial/territorial negotiations for brand name and generic drugs in Canada to achieve greater value for publicly funded drug programs and patients. Due to combined "buying power" of drug plans across multiple provinces and territories, the PCPA aims to:

a. Achieve lower drug costs and consistent pricing,
b. Increase access to drug treatment options, and
c. Improve consistency of coverage criteria across Canada.

More information on the **Pan-Canadian Pharmaceutical Alliance can be found here:**

http://www.canadaspremiers.ca/pan-canadian-pharmaceutical-alliance/

All drugs listed on the NLPDP benefit list must receive a recommendation for coverage from one of the committees above. Once recommended for coverage by the expert committee the department decides whether to list based on various factors including, but not limited to, budget impact and plan mandate.

It is important to note that the NLPDP will consider funding drugs only where there is evidence, cost-effectiveness and Health Canada approval. If a manufacturer is studying a drug for a new indication it is the responsibility of the manufacturer to provide funding or patient access as part of their clinical trial.